New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 17, 2014
12:13 EDTELOSSyneron Medical recommend following FDA clearance at Maxim
Maxim recommends investors continue buying shares of Syneron Medical following the FDA clearance of UltraShape. Maxim says UltraShape expands the base of body shaping treatments that physicians may use with complimentary Syneron systems and it keeps a Buy rating on the stock with a $16 price target.
News For ELOS From The Last 14 Days
Check below for free stories on ELOS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 6, 2014
13:22 EDTELOSSyneron Medical should be bought at current levels, says Maxim
After Syneron reported better than expected Q2 results, Maxim believes the company's sooner than expected ramp of two new product initiatives is positive. The firm thinks the company is poised to perform well in 2H14 and 2015.
07:06 EDTELOSSyneron Medical reports Q2 adjusted EPS 7c, consensus 7c
Reports Q2 revenue $64.6M, consensus $63.52M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use